IGF1 and portal hypertension: In a study investigating the response of IGF-I levels to GH replacement therapy in pediatric patients with CLD [42], it was reported that hepatic GH resistance is identified early in the disease process and becomes more pronounced as the disease progresses, especially in association with portal hypertension.